Saint Luke's Cancer Institute at Saint Luke's Hospital

Summary

Saint Luke's Cancer Institute at Saint Luke's Hospital is a medical facility located in Kansas City, Missouri. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Pancreatic Cancer, Colorectal Cancer and other specialties. Saint Luke's Cancer Institute at Saint Luke's Hospital is involved with conducting 115 clinical trials across 182 conditions. There are 3 research doctors associated with this hospital, such as Timothy Pluard, Janakiraman Subramanian, and Shahzad Raza, MD.

Top PIs

Clinical Trials running at Saint Luke's Cancer Institute at Saint Luke's Hospital

Breast Cancer

Pancreatic Cancer

Colorectal Cancer

Cancer

Lung Cancer

Endometrial Cancer

Ovarian Cancer

Brain Cancer

Brain Tumor

Bladder Cancer

Zanidatamab vs Trastuzumab

for Breast Cancer

The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician's choice of chemotherapy will be evaluated for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, previous T-DXd treatment.

Recruiting

2 awards

Phase 3

4 criteria

Lasofoxifene and Abemaciclib vs Fulvestrant and Abemaciclib

for Breast Cancer

The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palbociclib-based treatment and have locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation. The main question the study aims to answer is: • To compare the efficacy of the combination of lasofoxifene and abemaciclib with that of fulvestrant and abemaciclib Participants will receive either receive 5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day or the combination of fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day.

Recruiting

2 awards

Phase 3

12 criteria

Gedatolisib Combination

for Breast Cancer

This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant and CDK4/6 Inhibitors for the treatment of patients with locally advanced or metastatic HR+/HER2- advanced breast cancer.

Recruiting

2 awards

Phase 3

6 criteria